Cumberland Pharmaceuticals Inc. – Recent Trading Performance and Context
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) finished the trading day on Thursday, 22 October 2026, at a price of US $8.17 per share. The share price rose by 2.64 % over the 24‑hour period ending at 02:06 PM Central Europe time, reflecting a modest but positive market sentiment toward the company.
Market Overview
- Shares Outstanding: 15 million
- Market Capitalisation: US $122.4 million
- 24‑Hour Volume: Approximately US $1.2 million of trading activity
- Year‑to‑Date Performance: Since the close of the previous month, Cumberland’s share price has declined by 0.37 %.
- Simple Moving Average (200 days): US $5.49
- 52‑Week High / Low: The highest price recorded in the past year was US $9.28 on 26 August 2026, while the lowest was US $1.85 on 18 November 2025.
These metrics indicate a relatively stable valuation profile, with the current price comfortably above the 200‑day moving average and well above the recent low but still below the historical high. Investors can interpret the 2.64 % intraday gain as a short‑term bullish signal, though the broader trend remains neutral over the longer term.
Peer Performance Snapshot
The following table summarizes the performance of several peer stocks during the same 24‑hour interval:
| Symbol | 24‑Hour Change | Current Price | Market Cap (US $M) | P/E Ratio |
|---|---|---|---|---|
| EML | +0.58 % | US $24.31 | 146.3 | 18.81 |
| FINW | –1.04 % | US $10.46 | 145.2 | 14.47 |
| CMPX | –2.16 % | US $0.81 | 146.7 | — |
| LEE | +2.18 % | US $6.55 | 142.9 | — |
| ABOS | +0.74 % | US $2.03 | 145.7 | — |
Cumberland’s movement aligns with a modestly positive trend observed in several peers, particularly LEE and ABOS, which both posted gains above 2 %. In contrast, FINW and CMPX experienced declines, illustrating sector‑specific dynamics that may influence Cumberland’s performance.
Company Profile
Cumberland Pharmaceuticals Inc. is headquartered in Nashville, Tennessee, and specialises in the acquisition, development, and marketing of prescription products. The company’s product pipeline focuses on critical care, emergency medicine, and gastroenterology. Since its initial public offering in August 2009, Cumberland has built a diversified portfolio of therapeutic offerings, aiming to address unmet needs in high‑impact clinical areas.
Investors interested in learning more about Cumberland’s strategic initiatives, clinical trials, and regulatory milestones may consult the company’s public disclosures and investor relations materials available on the company website at www.cumberlandpharma.com . The stock continues to trade on the Nasdaq exchange, providing liquidity and access to a broad investor base.
